Randomized Trial of Valganciclovir Versus Valacyclovir Prophylaxis for Prevention of Cytomegalovirus in Renal Transplantation | Zendy

Tomáš Reischig | Zendy; Martin Kacer | Zendy; Pavel Jindra | Zendy; Ondřej Hes | Zendy; Daniel Lysák | Zendy; Mirko Bouda | Zendy

Open Access

Randomized Trial of Valganciclovir Versus Valacyclovir Prophylaxis for Prevention of Cytomegalovirus in Renal Transplantation

Author(s) -

Tomáš Reischig,

Martin Kacer,

Pavel Jindra,

Ondřej Hes,

Daniel Lysák,

Mirko Bouda

Publication year - 2014

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.07020714

Subject(s) - valganciclovir , medicine , hazard ratio , valaciclovir , cytomegalovirus , confidence interval , ganciclovir , basiliximab , randomized controlled trial , transplantation , incidence (geometry) , gastroenterology , kidney transplantation , human cytomegalovirus , immunology , herpesviridae , human immunodeficiency virus (hiv) , virus , physics , viral disease , optics

Both valganciclovir and high-dose valacyclovir are recommended for cytomegalovirus prophylaxis after renal transplantation. A head-to-head comparison of both regimens is lacking. The objective of the study was to compare valacyclovir prophylaxis with valganciclovir, which constituted the control group.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research